Selected aspects of polycystic ovarian disease.
Although there is general agreement about the polycystic ovary as an anatomic entity, a classic description of an associated syndrome remains elusive. This lack of definition, however, has not impeded clinical investigation. This article focuses on the diagnosis, pathogenesis, hypotheses, and treatment of polycystic ovarian disease.
Goldzieher
J W
JW
Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas.
Young
R L
RL
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D002996:Clomiphene / Q000627:therapeutic use; D003276:Contraceptives, Oral / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006062:Gonadotropins / Q000627:therapeutic use; D006801:Humans; D010535:Laparoscopy; D011085:Polycystic Ovary Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000601:surgery; D011374:Progesterone / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D003276:Contraceptives, Oral; D006062:Gonadotropins; D002996:Clomiphene; D007987:Gonadotropin-Releasing Hormone; D001971:Bromocriptine; D011374:Progesterone; D003907:Dexamethasone